JAYTHARI Oral Suspension (deflazacort) NDC 81806-213

NDC codes

FDA NDC Directory

Product NDC (as listed)81806-213Labeler and product segments. Claims need a package NDC.

Product NDC at billing width81806-0213Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
81806-213-13	81806021313	1 BOTTLE in 1 CARTON (81806-213-13) / 13 mL in 1 BOTTLEMarketed from Nov 20, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): JAYTHARI Oral Suspension
Generic name (nonproprietary): deflazacort
Active ingredients: Deflazacort — 22.75 mg/mL
Dosage form: Suspension
Route: Oral
Labeler: Doppel Farmaceutici S.r.l.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 220042
Marketing start: Nov 20, 2025
Listing expires: Dec 31, 2027
Other FDA classes: Corticosteroid Hormone Receptor Agonists (Mechanism)
Identifiers: Product ID 81806-213_5b226f70-c857-820c-e063-6294a90a4441SPL ID 5b226f70-c857-820c-e063-6294a90a4441SPL set ID 43f3890e-0b1d-9bb5-e063-6294a90aa622RxCUI 1870964, 2727381UNII KR5YZ6AE4B
Pharmacologic class: Corticosteroid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N481806021313 followed by a unit qualifier and the quantity

Package 81806-0213-13. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Sep 10, 2026.

Indications (excerpt from the label)

JAYTHARI is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. JAYTHARI is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 220042

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 220042
Product	Strength	Form · route	Labeler	Product NDC
Deflazacort Oral Suspensiondeflazacort	Deflazacort 22.75 mg/mL	SuspensionOral	Zydus Pharmaceuticals (USA) Inc.	70710-2007
Deflazacort Oral Suspensiondeflazacort	Deflazacort 22.75 mg/mL	SuspensionOral	Doppel Farmaceutici S.r.l.	81806-200
JAYTHARI Oral Suspensiondeflazacort	Deflazacort 22.75 mg/mL	SuspensionOral	Zydus Pharmaceuticals (USA) Inc.	70710-2131